60 Degrees Pharmaceuticals, Inc. Common Stock Total Liabilities
60 Degrees Pharmaceuticals, Inc. Common Stock total liabilities. Based on the latest financial reports, 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) has total liabilities worth $1.75 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 60 Degrees Pharmaceuticals, Inc. Common liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of 60 Degrees Pharmaceuticals, Inc. Common Stock (2020–2025)
Total liabilities of 60 Degrees Pharmaceuticals, Inc. Common Stock from 2020 to 2025. This chart illustrates how 60 Degrees Pharmaceuticals, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
60 Degrees Pharmaceuticals, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of 60 Degrees Pharmaceuticals, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GRI Bio Inc.
NASDAQ:GRI
|
USA | $1.10 Million |
|
CHRISTINA LAKE CANNABIS
F:CLB
|
Germany | €9.97 Million |
|
Ankit Metal & Power Limited
NSE:ANKITMETAL
|
India | Rs10.32 Billion |
|
Guard Therapeutics International AB
ST:GUARD
|
Sweden | Skr15.24 Million |
|
Korea SE Corp
KQ:101670
|
Korea | ₩16.53 Billion |
|
De La Rue PLC
LSE:DLAR
|
UK | GBX298.90 Million |
|
Monsenso AS
CO:MONSO
|
Denmark | Dkr4.08 Million |
|
Kaixin Auto Holdings
NASDAQ:KXIN
|
USA | $11.09 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down 60 Degrees Pharmaceuticals, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SXTP total asset value.
Liquidity & Leverage Metrics
60 Degrees Pharmaceuticals, Inc. Common Stock Total Liabilities Ratios Explained
60 Degrees Pharmaceuticals, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 60 Degrees Pharmaceuticals, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 60 Degrees Pharmaceuticals, Inc. Common Stock (2020–2025)
The table below shows the annual total liabilities of 60 Degrees Pharmaceuticals, Inc. Common Stock from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.99 Million | +10.11% |
| 2024-12-31 | $1.80 Million | -39.57% |
| 2023-12-31 | $2.99 Million | -88.27% |
| 2022-12-31 | $25.45 Million | +30.17% |
| 2021-12-31 | $19.55 Million | -5.46% |
| 2020-12-31 | $20.68 Million | -- |
About 60 Degrees Pharmaceuticals, Inc. Common Stock
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications… Read more